JP2023514407A5 - - Google Patents
Info
- Publication number
- JP2023514407A5 JP2023514407A5 JP2022550184A JP2022550184A JP2023514407A5 JP 2023514407 A5 JP2023514407 A5 JP 2023514407A5 JP 2022550184 A JP2022550184 A JP 2022550184A JP 2022550184 A JP2022550184 A JP 2022550184A JP 2023514407 A5 JP2023514407 A5 JP 2023514407A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- cells
- immune cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980914P | 2020-02-24 | 2020-02-24 | |
| US62/980,914 | 2020-02-24 | ||
| US202063020713P | 2020-05-06 | 2020-05-06 | |
| US63/020,713 | 2020-05-06 | ||
| US202063053409P | 2020-07-17 | 2020-07-17 | |
| US63/053,409 | 2020-07-17 | ||
| US202063092681P | 2020-10-16 | 2020-10-16 | |
| US63/092,681 | 2020-10-16 | ||
| PCT/US2021/019362 WO2021173630A1 (en) | 2020-02-24 | 2021-02-24 | Bcma car-t cells with enhanced activities |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023514407A JP2023514407A (ja) | 2023-04-05 |
| JP2023514407A5 true JP2023514407A5 (https=) | 2024-03-04 |
Family
ID=75108802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550184A Pending JP2023514407A (ja) | 2020-02-24 | 2021-02-24 | 増強された活性を有するｂｃｍａ ｃａｒ－ｔ細胞 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12036243B2 (https=) |
| EP (1) | EP4110805A1 (https=) |
| JP (1) | JP2023514407A (https=) |
| KR (1) | KR20220145846A (https=) |
| CN (1) | CN115175929A (https=) |
| AU (1) | AU2021227191A1 (https=) |
| BR (1) | BR112022016657A2 (https=) |
| CA (1) | CA3167065A1 (https=) |
| CO (1) | CO2022011684A2 (https=) |
| IL (1) | IL295470A (https=) |
| MX (1) | MX2022010340A (https=) |
| PE (1) | PE20221757A1 (https=) |
| PH (1) | PH12022552033A1 (https=) |
| TW (1) | TWI894211B (https=) |
| WO (1) | WO2021173630A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115427440A (zh) * | 2020-02-25 | 2022-12-02 | 圭尔医疗有限公司 | 用于工程化细胞的嵌合受体 |
| JP2024517413A (ja) | 2021-04-16 | 2024-04-22 | セルジーン コーポレーション | 以前に幹細胞移植を受けた患者におけるｔ細胞療法 |
| KR20240112994A (ko) | 2021-11-03 | 2024-07-19 | 셀진 코포레이션 | 골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체 |
| KR20240137075A (ko) | 2022-01-28 | 2024-09-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 조성물의 제조 방법 |
| US20250295771A1 (en) | 2022-05-11 | 2025-09-25 | Celgene Corporation | Methods and uses related to t cell therapy and production of same |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
| EP4532695A1 (en) | 2022-05-25 | 2025-04-09 | Celgene Corporation | Methods of manufacturing t cell therapies |
| CA3261440A1 (en) | 2022-07-29 | 2024-02-01 | Allogene Therapeutics, Inc. | MODIFIED CELLS WITH REDUCED GENE EXPRESSION TO MITIGATE RECOGNITION BY IMMUNE CELLS |
| CN119836438A (zh) * | 2022-09-19 | 2025-04-15 | 艾洛基治疗公司 | B-细胞成熟抗原（bcma）抗独特型抗体 |
| WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| WO2024168192A1 (en) | 2023-02-10 | 2024-08-15 | Celgene Corporation | Assessment of bcma in biological samples |
| CN121532650A (zh) | 2023-06-20 | 2026-02-13 | 艾洛基治疗公司 | 工程化的细胞的检测方法 |
| US20260108629A1 (en) * | 2024-08-14 | 2026-04-23 | Kite Pharma, Inc. | Vectors for production of therapeutic constructs |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| AU3668897A (en) | 1996-07-17 | 1998-02-09 | University Of Medicine And Dentistry Of New Jersey | Chimeric receptors for jak-stat signal transduction |
| WO2007075899A2 (en) | 2005-12-21 | 2007-07-05 | Maxygen, Inc. | Dual agonist compounds and uses thereof |
| SI2856876T1 (en) | 2007-03-30 | 2018-04-30 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| CA2738031C (en) | 2008-09-22 | 2022-11-29 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters |
| WO2011069004A1 (en) | 2009-12-04 | 2011-06-09 | Quest Diagnostics Investments Incorporated | Mpl mutations in jak2 v617f negative patients with myeloproliferative disease |
| CA2832569A1 (en) | 2011-04-08 | 2012-10-11 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| BR112014029417B1 (pt) | 2012-05-25 | 2023-03-07 | Cellectis | Método ex vivo para a preparação de células t para imunoterapia |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| CA2905352A1 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| ES2791598T3 (es) | 2013-06-05 | 2020-11-05 | Bellicum Pharmaceuticals Inc | Métodos para inducir apoptosis parcial utilizando polipéptidos de caspasa |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| BR112017007003A2 (pt) | 2014-10-07 | 2017-12-19 | Cellectis | método para modulação de atividade de células imunes induzidas por car |
| HK1245827B (en) | 2014-12-15 | 2020-06-19 | Board Of Regents Of The University Of Texas System | Methods for controlled activation or elimination of therapeutic cells |
| BR112017013981A2 (pt) | 2015-01-26 | 2018-01-02 | Cellectis | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer |
| WO2016127257A1 (en) | 2015-02-12 | 2016-08-18 | University Health Network | Chimeric antigen receptors |
| US10294304B2 (en) * | 2015-04-13 | 2019-05-21 | Pfizer Inc. | Chimeric antigen receptors targeting B-cell maturation antigen |
| TWI703159B (zh) * | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| US20180318303A1 (en) | 2015-04-15 | 2018-11-08 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
| KR20230167769A (ko) * | 2016-08-26 | 2023-12-11 | 베이롤 칼리지 오브 메드신 | 세포 치료요법을 위한 항상성 활성 사이토킨 수용체 |
| MA46862A (fr) | 2016-11-17 | 2019-09-25 | Bluebird Bio Inc | Convertisseur de signaux tgf béta |
| US20190358263A1 (en) | 2016-12-07 | 2019-11-28 | Oslo Universitetssykehus Hf | Compositions and Methods for Cell Therapy |
| GB201702617D0 (en) | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
| KR102879522B1 (ko) | 2017-03-03 | 2025-11-04 | 엑수마 바이오테크, 코포레이션 | 림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물 |
| WO2018182935A1 (en) * | 2017-03-31 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Synthekine compositions and methods of use |
| EP3735460A4 (en) | 2017-09-18 | 2021-08-11 | Exuma Biotech Corp. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY OF THE LATTER |
| GB201719557D0 (en) | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| US11738047B2 (en) | 2017-12-12 | 2023-08-29 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof |
| CN111819192A (zh) * | 2018-03-02 | 2020-10-23 | 艾洛基治疗公司 | 可诱导的嵌合细胞激素受体 |
| EP3802578A4 (en) * | 2018-06-01 | 2022-03-23 | Washington University | SUPPRESSION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR CELL THERAPY |
| CA3102641A1 (en) | 2018-06-22 | 2019-12-26 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| AU2020232216B2 (en) * | 2019-03-01 | 2025-09-25 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a PD-1 ectodomain |
| PE20211902A1 (es) * | 2019-03-01 | 2021-09-27 | Allogene Therapeutics Inc | Receptores de citocinas quimericos constitutivamente activos |
-
2021
- 2021-02-24 MX MX2022010340A patent/MX2022010340A/es unknown
- 2021-02-24 US US17/183,689 patent/US12036243B2/en active Active
- 2021-02-24 CA CA3167065A patent/CA3167065A1/en active Pending
- 2021-02-24 TW TW110106494A patent/TWI894211B/zh active
- 2021-02-24 PE PE2022001799A patent/PE20221757A1/es unknown
- 2021-02-24 CN CN202180016621.7A patent/CN115175929A/zh active Pending
- 2021-02-24 JP JP2022550184A patent/JP2023514407A/ja active Pending
- 2021-02-24 EP EP21713206.7A patent/EP4110805A1/en active Pending
- 2021-02-24 KR KR1020227030983A patent/KR20220145846A/ko active Pending
- 2021-02-24 AU AU2021227191A patent/AU2021227191A1/en active Pending
- 2021-02-24 IL IL295470A patent/IL295470A/en unknown
- 2021-02-24 WO PCT/US2021/019362 patent/WO2021173630A1/en not_active Ceased
- 2021-02-24 PH PH1/2022/552033A patent/PH12022552033A1/en unknown
- 2021-02-24 BR BR112022016657A patent/BR112022016657A2/pt not_active IP Right Cessation
-
2022
- 2022-08-19 CO CONC2022/0011684A patent/CO2022011684A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023514407A5 (https=) | ||
| JP7836847B2 (ja) | 二重特異性キメラ抗原受容体およびその治療的使用 | |
| JP2023139070A5 (https=) | ||
| CN111527109B (zh) | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 | |
| JP2020096630A5 (https=) | ||
| US9868961B2 (en) | Methods and compositions for localized secretion of anti-CTLA-4 antibodies | |
| CA2926267C (en) | Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors | |
| CN112074278B (zh) | Bcma-car-t细胞 | |
| KR20240037892A (ko) | 클라우딘 18.2 t 세포-항원 커플러 및 이의 용도 | |
| JP2022506598A5 (https=) | ||
| JP2014532074A5 (https=) | ||
| JP2022512882A5 (https=) | ||
| JP2020512019A5 (https=) | ||
| AU2016313107A1 (en) | Conditionally active chimeric antigen receptors for modified T-cells | |
| CA3177234A1 (en) | Fully humanized bispecific chimeric antigen receptor targeting cd19 and cd22 and use thereof | |
| JP2022521240A5 (https=) | ||
| JP2019536469A5 (https=) | ||
| JP2023553049A (ja) | Ｃｄ１９＋、ｃｄ２０＋、若しくはｃｄ２２＋腫瘍又はｂ細胞由来の自己免疫疾患を治療するためのｃａｒ ｔ細胞 | |
| CN110938148A (zh) | 靶向cd19和cd22嵌合抗原受体 | |
| CN114286691B (zh) | Cs1-抗体和抗cs1-car-t细胞 | |
| JPWO2017195749A1 (ja) | キメラ抗原受容体、及びその利用 | |
| JP7619682B2 (ja) | Ｃｄ２２に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体 | |
| KR20230143108A (ko) | Cd30 유래의 세포내 신호전달 도메인을 포함하는 키메라 항원 수용체, 이를 발현하는 면역세포 및 이들의 용도 | |
| EP4301402A1 (en) | Bispecific antibodies enhancing cell mediated immune responses | |
| WO2023016554A1 (zh) | 靶向cd22的抗原结合蛋白及其用途 |